Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage.
BACKGROUND
Current transfusion-related acute lung injury reduction strategies include avoiding transfusion of plasma products collected from female donors or female donors that have been pregnant to reduce transfusion of plasma-containing HLA antibodies. Such a policy considerably decreases the number of donors available for generation of fresh-frozen plasma (FFP). To increase the supply of FFP, substitution of 24-hour plasma (FP24) and thawed plasma (TP) derived from either FFP or FP24 may be viable substitutes. To justify such a policy the coagulation factor content of FFP, FP24, and TP derived from both product types was assessed.


METHODS
Coagulation factor (F)II, FV, FVII, FVIII, F IX, and FX; protein C (PC) and protein S (PS); von Willebrand factor antigen and ristocetin cofactor; fibrinogen; and antithrombin activities were analyzed in nonpaired FFP and FP24 at the time of product thaw and again after 120 hours of 1 to 6°C storage.


RESULTS
At thaw, mean FVIII and PC activities were lower in FP24 than FFP. Mean PC and PS activities were lower in FP24- than FFP-derived 120-hour-old TP. No other differences in mean activity reached significance. Activity levels were generally lower in TP; FVIII, FV, and FVII showed the largest changes. However, prestorage leukoreduction appears to improve the stability of FV.


CONCLUSIONS
FFP, FP24, and the derived TP all contain adequate coagulation factor activities to maintain hemostatic activity. As FFP becomes less available, increased use of FP24 and TP are viable alternatives for most clinical situations.
Scott
Erik
E
BloodCenter of Wisconsin, Inc., 638 N. 18th Street, Milwaukee,WI 53201, USA. erik.scott@bcw.edu
Puca
Kathleen
K
Heraly
Jennifer
J
Gottschall
Jerome
J
Friedman
Kenneth
K
D055371:Acute Lung Injury / Q000517:prevention & control; D001779:Blood Coagulation Factors / Q000032:analysis*; D001780:Blood Coagulation Tests / Q000379:methods; D016913:Blood Component Transfusion / Q000009:adverse effects; D001782:Blood Donors; D015925:Cryopreservation; D005260:Female; D006801:Humans; D008297:Male; D010949:Plasma / Q000737:chemistry*; D011247:Pregnancy; D012034:Refrigeration; D012737:Sex Factors; D013997:Time Factors
D001779:Blood Coagulation Factors